Myovant Sciences's total inventories for the quarter that ended in Mar. 2022 was $7.6 Mil. Myovant Sciences's average total inventories from the quarter that ended in Dec. 2021 to the quarter that ended in Mar. 2022 was $7.2 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Myovant Sciences's Net-Net Working Capital per share for the quarter that ended in Mar. 2022 was $-5.67.
Inventory can be measured by days sales of inventory (DSI).
Myovant Sciences's days sales of inventory (DSI) for the
three
months ended in Mar. 2022 was 11.35.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Myovant Sciences's Days Inventory for the
three
months ended in Mar. 2022 was 36.83.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Myovant Sciences's Inventory Turnover for the quarter that ended in Mar. 2022 was 2.48.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Myovant Sciences's Inventory-to-Revenue for the quarter that ended in Mar. 2022 was 0.12.
Myovant Sciences Total Inventories Historical Data
The historical data trend for Myovant Sciences's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Total Inventories
-
-
-
2.61
7.58
Myovant Sciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Total Inventories
2.61
4.17
6.14
6.74
7.58
Myovant Sciences Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Myovant Sciences (NYSE:MYOV) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Myovant Sciences's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2022 is
5. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Myovant Sciences's Inventory to Revenue for the quarter that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Myovant Sciences Total Inventories Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.81(8.08%) Volume: 603,321 4:01PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
